December 2012. Volume 8. Number 4

Esomeprazole does not improve gastroesophageal reflux disease symptoms in children less than one year

 
 
 
 
 
 
 
 
 
 
Rating: 4 (1 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Winter H, Gunasekaran T, Tolia V, Gottrand F, Barker PN, Illueca M. Esomeprazole for the treatment of GERD in infants ages 1-11 months. J Pediatr Gastroenterol Nutr. 2012;55:14-20.
Reviewers: Molina Arias M1, Ortega Páez E2.
1Servicio de Gastroenterología y Nutrición. Hospital Infantil Universitario La Paz. Madrid. España.
2CS Maracena. Distrito metropolitano. Granada. España.
Correspondence: Manuel Molina Arias. Email: mma1961@gmail.com
Reception date: 12/10/2012
Acceptance date: 22/10/2012
Publication date: 31/10/2012

Abstract

Authors' conclusions: esomeprazole treatment does not reduce the discontinuation rate owing to symptoms worsening in children with gastroesophageal reflux disease. Improved diagnostic criteria may help to identify reflux patients who may benefit from this treatment.

Reviewers' commentary: esomeprazole treatment does not influence the clinical outcome of infants with gastroesophageal reflux. These results are expected due to the inclusion criteria used in the study, but they probably would be different if treatment were limited only to children with proven peptic disease and gastrointestinal symptoms.

How to cite this article

Molina Arias M, Ortega Páez E. El esomeprazol no mejora los síntomas de enfermedad por reflujo gastroesofágico en menores de un año. Evid Pediatr. 2012;8:78.

AVC | Critically appraised articles

Winter H, Gunasekaran T, Tolia V, Gottrand F, Barker PN, Illueca M. Esomeprazole for the treatment of GERD in infants ages 1-11 months. J Pediatr Gastroenterol Nutr. 2012;55:14-20.
Reviewers: Molina Arias M1, Ortega Páez E2.
1Servicio de Gastroenterología y Nutrición. Hospital Infantil Universitario La Paz. Madrid. España.
2CS Maracena. Distrito metropolitano. Granada. España.
Correspondence: Manuel Molina Arias. Email: mma1961@gmail.com
Reception date: 12/10/2012
Acceptance date: 22/10/2012
Publication date: 31/10/2012

How to cite this article

Molina Arias M, Ortega Páez E. El esomeprazol no mejora los síntomas de enfermedad por reflujo gastroesofágico en menores de un año. Evid Pediatr. 2012;8:78.

References

  1. van der Pol RJ, Smits MJ, van Wijk MP, Omari TI, Tabbers MM, Benninga MA. Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review. Pediatrics. 2011;127:925-35.
  2. Hassall E. Over-prescription of acid-supressing medications in infants: how it came about, why it’s wrong, and what to do about it. J Pediatr. 2012;160:193-8.
  3. Gilger MA, Tolia V, Vandenplas Y, Youssef NN, Traxler B, Illueca M. Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease. JPGN. 2008;46:524-33.
  4. Tolia V, Gilger MA, Barker PN, Illueca M. Healing of erosive esophagitis and improvement of symptoms of gastroesophageal reflux disease after esomeprazole treatment in children 12 to 36 months old. JPGN. 2010;51:593-8.
  5. Chen IL, Gao WY, Johnson AP, Niak A, Triani J, Korvick J, et al. Proton pump inhibitor use in infants: FDA reviewer experience. JPGN. 2012;54:8-14.
  6. Ortega Páez E, Cuestas Montañés E. Reflujo gastroesofágico: los inhibidores de la bomba de protones no mejoran la sintomatología en lactantes. Evid Pediatr. 2012;8:39.
31/10/2012

Linked Comment